Osteoblastic bone lesion

An osteoblastic bone lesion is a region of abnormally increased bone formation in the skeleton, most commonly arising due to the spread (metastasis) of cancers such as prostate cancer to bone. These lesions are called "osteoblastic" or "sclerotic" because of the excessive deposition of new but structurally abnormal bone, resulting from tumor-induced stimulation of osteoblasts. Osteoblastic lesions are contrasted with "osteolytic" lesions, which involve bone destruction. In metastatic bone disease, osteoblastic lesions are most frequently seen with prostate, bladder, and stomach cancers, and may occur as mixed lesions with breast cancer. Although new bone forms, it is weak and prone to deformation or fracture. Osteoblastic lesions do not describe a druggable or molecular target but a pathological outcome due to tumor–bone cell interactions. It is a descriptive term for a bone pathology resulting from increased osteoblast-mediated bone formation, usually secondary to cancer metastasis. It is not a molecular target but a clinical and radiological feature of advanced cancer. These lesions are diagnosed and monitored via radiology (CT, MRI, bone scans).

Other names

Sclerotic bone lesionOsteoblastic bone metastasisBlastic bone lesionSclerotic metastasis

While "osteoblastic bone lesion" is not a therapeutic target itself, drugs used in its management address underlying pathological processes. Bisphosphonates and denosumab primarily target bone turnover, reducing bone resorption and complications. Other investigational therapies aim to inhibit molecular pathways involved in lesion formation, such as the endothelin-1 pathway, TGF-β, and Src-family kinases, via specific inhibitors (e.g., endothelin receptor antagonists, TGF-β inhibitors, Src inhibitors like dasatinib).